These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37182063)

  • 1. Delayed Hyperpigmented Injection Site Reactions Due to Chronic Dupilumab Use.
    Pacheco CS; White KM
    Cureus; 2023 Apr; 15(4):e37441. PubMed ID: 37182063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis.
    Wechsler ME; Klion AD; Paggiaro P; Nair P; Staumont-Salle D; Radwan A; Johnson RR; Kapoor U; Khokhar FA; Daizadeh N; Chen Z; Laws E; Ortiz B; Jacob-Nara JA; Mannent LP; Rowe PJ; Deniz Y
    J Allergy Clin Immunol Pract; 2022 Oct; 10(10):2695-2709. PubMed ID: 35636689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dupilumab-induced skin-associated side effects in patients with chronic rhinosinusitis with nasal polyposis.
    Chromy D; Bartosik T; Brkic FF; Quint T; Tu A; Eckl-Dorna J; Schneider S; Bangert C
    J Dermatol; 2023 Jan; 50(1):89-93. PubMed ID: 36177732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dupilumab Adverse Events in Nasal Polyp Treatment: Analysis of FDA Adverse Event Reporting System.
    Swisher AR; Kshirsagar RS; Adappa ND; Liang J
    Laryngoscope; 2022 Dec; 132(12):2307-2313. PubMed ID: 34918342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review.
    Neagu N; Dianzani C; Avallone G; Dell'Aquila C; Morariu SH; Zalaudek I; Conforti C
    J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):820-835. PubMed ID: 35122335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
    Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
    Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dupilumab for Atopic Dermatitis: The Silver Bullet We Have Been Searching for?
    Tameez Ud Din A; Malik I; Arshad D; Tameez Ud Din A
    Cureus; 2020 Apr; 12(4):e7565. PubMed ID: 32382467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients.
    Guex-Crosier Y; Di-Lucca J; Häusermann P; Laffitte E; Saulite I; Schmid-Grendelmeier P; Schürch K; Thormann K; Simon D
    Swiss Med Wkly; 2021 Aug; 151():w30020. PubMed ID: 34495603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exacerbation of Eosinophilic Granulomatosis With Polyangiitis After Administering Dupilumab for Severe Asthma and Eosinophilic Rhinosinusitis With Nasal Polyposis.
    Tanaka S; Tsuji T; Shiotsu S; Yuba T; Hiraoka N
    Cureus; 2022 May; 14(5):e25218. PubMed ID: 35747049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis.
    Jonstam K; Swanson BN; Mannent LP; Cardell LO; Tian N; Wang Y; Zhang D; Fan C; Holtappels G; Hamilton JD; Grabher A; Graham NMH; Pirozzi G; Bachert C
    Allergy; 2019 Apr; 74(4):743-752. PubMed ID: 30488542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous treatment of Samter triad and prurigo nodularis with dupilumab.
    Bloomstein JD; Hawkes JE
    JAAD Case Rep; 2021 Dec; 18():20-22. PubMed ID: 34778501
    [No Abstract]   [Full Text] [Related]  

  • 12. Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis.
    Napolitano M; Maffei M; Patruno C; Leone CA; Di Guida A; Potestio L; Scalvenzi M; Fabbrocini G
    Dermatol Ther; 2021 Nov; 34(6):e15120. PubMed ID: 34472171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab for prurigo nodularis: Case series and review of the literature.
    Holm JG; Agner T; Sand C; Thomsen SF
    Dermatol Ther; 2020 Mar; 33(2):e13222. PubMed ID: 31917498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases.
    Kychygina A; Cassagne M; Tauber M; Galiacy S; Paul C; Fournié P; Simon M
    Clin Rev Allergy Immunol; 2022 Jun; 62(3):519-533. PubMed ID: 35275334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response.
    Husein-ElAhmed H; Steinhoff M
    J Dermatolog Treat; 2022 May; 33(3):1547-1553. PubMed ID: 33200955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dupilumab for atopic dermatitis: evidence to date.
    Rodrigues MA; Nogueira M; Torres T
    G Ital Dermatol Venereol; 2019 Dec; 154(6):696-713. PubMed ID: 31210470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma.
    Laidlaw TM; Bachert C; Amin N; Desrosiers M; Hellings PW; Mullol J; Maspero JF; Gevaert P; Zhang M; Mao X; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Staudinger H; Mannent LP
    Ann Allergy Asthma Immunol; 2021 May; 126(5):584-592.e1. PubMed ID: 33465455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse effects of dupilumab in chronic rhinosinusitis with nasal polyps. Case report and narrative review.
    Nitro L; Bulfamante AM; Rosso C; Saibene AM; Arnone F; Felisati G; Pipolo C
    Acta Otorhinolaryngol Ital; 2022 Jun; 42(3):199-204. PubMed ID: 35880360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dupilumab in the treatment of chronic rhinosinusitis with nasal polyposis.
    Boyle JV; Lam K; Han JK
    Immunotherapy; 2020 Feb; 12(2):111-121. PubMed ID: 32075470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review.
    Hendricks AJ; Yosipovitch G; Shi VY
    J Dermatolog Treat; 2021 Feb; 32(1):19-28. PubMed ID: 31693426
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.